免疫检查点的翻译后修改:释放癌症免疫治疗中的新潜力
Qiongjie Hu1,2, Yueli Shi1,3, Huang Wang4
1Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, 322000, Zhejiang Province, China.
Experimental hematology & oncology
|March 15, 2025
概括
增强癌症免疫疗法包括准后翻译性修饰 (PTMs),如ubiquitination,酸化和糖化. 调节这些PTM提供了一种有希望的策略,以提高免疫检查点阻塞 (ICB) 治疗的疗效和克服耐药性.
科学领域:
- 免疫学和癌症治疗学
- 分子生物学和蛋白质修饰
背景情况:
- 免疫检查点阻塞 (ICB) 疗法在癌症治疗中表现有前途,但面临着适度反应率,药物耐药性和不良影响的挑战.
- 对于提高当前ICB疗法的有效性有必要制定战略.
研究的目的:
- 审查后翻译修改 (PTM) 在调节免疫检查点信号传递中的重要作用.
- 探索如何针对特定的PTM可以导致新的免疫治疗方法.
主要方法:
- 文献综述侧重于无处不在化,酸化和糖化.
- 分析这些PTM对免疫检查点蛋白表达和功能的影响.
- 在ICB的背景下,检查针对PTM的新兴治疗策略.
主要成果:
- 翻译后的修改极大地影响了免疫检查点蛋白的功能和调节.
- 特定的PTM,包括无处不在,酸化和糖化,直接调节免疫检查点信号通路.
- 针对这些PTM为开发下一代免疫疗法提供了一个可行的途径.
结论:
- 调节PTM提供了一个有希望的策略,以克服当前免疫检查点阻塞疗法的局限性.
- 未来对PTM的研究有可能优化癌症免疫疗法并改善患者的治疗结果.
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cytotoxic T Cells-mediated Immune Response
823
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
823
Cell-surface Signaling
51.4K
Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
51.4K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K


